Drugs / gucy2c cart cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04652219 | Oct 2020 → Oct 2021 | digestive system cancer | Weijia Fang, MD | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04780529 | Mar 2021 → Apr 2022 | digestive system cancer | Innovative Cellular Therapeutics Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gucy2c cart cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04652219 ↗ |
| Modality | Cell therapy | “Chimeric Antigen Receptor T Cells (CART) Therapy” NCT04780529 ↗ |
| Route | Other | “Patients with advanced malignant gastrointestinal tumors were injected with CART cells” NCT04780529 ↗ |